

**AQUARIUS SURGICAL TECHNOLOGIES REPORTS RESULTS OF
OPERATIONS FOR THE PERIOD ENDING DECEMBER 31, 2017**

Halifax, Nova Scotia, February 26, 2018; AQUARIUS SURGICAL TECHNOLOGIES INC. (ASTI – CSE) (“the Corporation”) today reports the results of operations for the three month and nine month periods ended December 31, 2017. All amounts referenced herein are in Canadian dollars.

The following table shows the results for the comparable periods:

Aquarius Surgical Technologies Inc. (formerly Aquarius Coatings Inc.) Condensed Consolidated Interim Statement of Comprehensive Loss (Unaudited)				
	Three Months Ended		Nine Months Ended	
	Dec 31, 2017	Dec 31, 2016	Dec 31, 2017	Dec 31, 2016
	\$	\$	\$	\$
Sales	200,818	-	553,690	-
Cost of sales (Note 6)	222,773	-	518,991	-
Gross Margin	(21,955)	-	34,698	-
Expenses				
General and administrative (Note 14)	387,308	33,158	1,070,243	75,046
Bank charges and interest	3,016	541	6,881	1,554
Amortization (Notes 7 and 8)	122,710	23	367,656	70
	513,034	33,722	1,444,780	76,670
Net loss before other items	(534,988)	(33,722)	(1,410,082)	(76,670)
Other items:				
Royalty income	-	3,061	2,592	8,219
Total comprehensive loss	(534,988)	(30,661)	(1,407,490)	(68,451)
Loss per share, basic and diluted	(\$0.029)	(\$0.006)	(\$0.079)	(\$0.013)
Weighted average number of shares outstanding	18,233,545	5,397,411	17,735,342	5,397,411

In the nine months ending December 31, 2017, the cost of sales consists of cost of goods sold of \$363,485, demonstration fibers and obsolete inventory \$96,429 and incoming shipping costs of \$59,077 (2016 - nil) in the statement of net loss and comprehensive loss.

The results in the current year include the operations of Surgical Lasers Inc. which was acquired effective from March 1, 2017. The per share amounts for the prior year have been adjusted to reflect the consolidation of the Corporations shares on a 1 for 20 basis effective February 24, 2017

Said Gordon Willox, Managing Director of Surgical Lasers Inc.: “The Sales for the Quarter reflect the predictably longer initial sales cycle associated with the introduction of new technology to the medical sector. In the case of Surgical Lasers Inc.’s flagship product; the MP200 high performance, portable laser, which facilitates a paradigm shift in the way minimally invasive Benign Prostatic Hyperplasia (BPH) treatments are delivered to patients, the sales cycle is approximately six months. This provides adequate time to learn the new technique, schedule patients for the treatments, and follow up (typically 90 days) to validate the proven clinical efficacy of the procedure. We are now at the point where our initial product evaluations are ready to commit to firm orders.

In addition, the company is experiencing strong demand for its new compact holmium laser, which is gaining momentum in the market as a true innovation in laser lithotripsy, applying engineering excellence to maximize performance and control in a practical, compact design. With continued and strengthened marketing initiatives, Surgical Lasers Inc. is looking towards continued growth and a significant increase in Sales for the Fourth Quarter of the current fiscal period, to March 31, 2018, reflecting growing sales of both of these laser platforms as well as the corresponding recurring revenue stream associated with single use consumable fibers used with every laser sold.”

The Corporation has filed its unaudited consolidated financial statements and management discussion and analysis for the third quarter ended December 31, 2017. Both are available under the Corporation's profile on SEDAR at www.sedar.com. These and other corporate filings are also available on the CSE website www.thecse.com under the Corporation’s symbol “ASTP”.

For further information, please contact:

N Gary Van Nest
Acting Chief Executive Officer
(647) 308-0685
Email: gary@sinaltainvestments.com

The Canadian Securities Exchange has neither approved nor disapproved of the information contained in this release. This Media Release may contain forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the success of the Corporation's sales strategies.